• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biogen adds to portfolio

Biogen adds to portfolio

March 7, 2011
CenterWatch Staff

Biogen Idec, which makes multiple sclerosis drugs Tysabri and Avonex, plans to build a portfolio of products to treat noncancerous blood disorders, according to Reuters.

The company's goal is to reduce its dependence on its MS products and build a new franchise around its experimental drugs to treat hemophilia. Biogen has two hemophilia products in phase III development.

"If we are going to build a commercial infrastructure that is going to call on hematologists, then we can think about other products in this area," George Scangos, Biogen's CEO, told Reuters. "We are actively looking to build a hematology franchise, and will consider acquisitions as well as in-licensing."

Weston, Mass.-based Biogen, which ended 2010 with $2 billion in cash and marketable securities, has sometimes been criticized for being too conservative, emphasizing stock buybacks over new product acquisitions. Between 2004 and 2010, Biogen returned $8 billion to shareholders in the form of stock repurchases.

Scangos, who took over as CEO last July, said the company will continue to buy back shares but also plans to be more aggressive in buying new products, especially those in early and mid-stage development.

"I don't think the two are mutually exclusive," he said. "We don't need any more phase III products right now, but we don't have enough compounds in phase I and phase II to generate a robust phase III pipeline some years down the road."

There are multiple treatments on the market for hemophilia. Currently the global market for one treatment, Factor VIII, products is about $5 billion, while the market for another, Factor IX, is worth about $1 billion. But the drugs, in general, must be infused three or more times a week.

Biogen's Factor IX product is designed to stay in the body up to three times longer than existing drugs, meaning patients would require an infusion only once a week. The company does not have data yet on exactly how much longer its Factor VIII product lasts.

While patients are typically reluctant to switch products, Scangos said he believes the attraction of fewer infusions will be a powerful motivator.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing